On March 17, 2020, SignPath Pharma issued a press release stating its intention to pursue a therapeutic treatment for COVID-19 with SignPath’s proprietary patented drug, Lipocurc™. LipoCurc suppresses inflammatory cytokines which can cause cytokine storm. Cytokine storm is believed by many experts to be a significant cause of the lung and organ damage suffered by some COVID-19 patients. SignPath believes that Lipocu
April 27, 2020
· 4 min read